Susan Orr
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Susan Orr
Non-Executive Director / Opthea
Dr Susan Orr is an experienced medical and business leader specialising in identifying, developing, and commercialising ophthalmic therapeutic product candidates.
Dr Orr has been the chief medical officer of Claris Biotherapeutics since February 2020, and is a member of the Retina Global board of directors. Prior to joining Claris, Dr Orr was the chief executive of Notal Vision. She had spent more than 30 years in the field of ophthalmology that also includes ten years in private optometric practice and leadership roles at Alcon and Janssen spanning international development, global new product strategy, and business development and licensing.
Dr Orr participated in multiple acquisitions including Durezol and Beovu (brolucizumab), and has been a managing partner of Fovendeye Consulting since 2016.
Dr Orr has been the chief medical officer of Claris Biotherapeutics since February 2020, and is a member of the Retina Global board of directors. Prior to joining Claris, Dr Orr was the chief executive of Notal Vision. She had spent more than 30 years in the field of ophthalmology that also includes ten years in private optometric practice and leadership roles at Alcon and Janssen spanning international development, global new product strategy, and business development and licensing.
Dr Orr participated in multiple acquisitions including Durezol and Beovu (brolucizumab), and has been a managing partner of Fovendeye Consulting since 2016.
Lists and Charts
Total Shareholder Return as at 29/11/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 291st | Opthea | 49% | -21% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Roles
Year started and most recent title
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Opthea | $980k |
1333 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Person Activity
| NEW ROLE: Non-Executive Director, Opthea | 26 May 2022 |
